Ddel-07intravenous Toca 511 Delivery Leads to Viral Dna in Resected HGG

Cloughesy, Timothy F.; Vogelbaum, Michael A.; Ostertag, Derek; Diego, Oscar; Jolly, Douglas J.; Ibáñez, Carlos; Yagiz, Kadir; Robbins, Joan; Chu, Alice; Niethammer, Andreas G.; Gruber, Harry E.; Kalkanis, Steven N.

doi:10.1093/neuonc/nov212.07

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While full patient details on IDH status were not published, authors did note that of the patients with complete responses, two were IDH-mut and three IDH-wt. In another phase I trial, NCT01985256, Toca 511 was given IV prior to recurrent HGG resection in addition to resection bed injection [ 48 ]. Ten patients were treated at the time of abstract publication.…”

Section: Murine Leukemia Virus-based Therapiesmentioning

confidence: 99%

Current Status and Challenges of Oncolytic Virotherapy for the Treatment of Glioblastoma

2023

View full text Add to dashboard Cite

Despite decades of research and numerous clinical trials, the prognosis of patients diagnosed with glioblastoma (GBM) remains dire with median observed survival at 8 months. There is a critical need for novel treatments for GBM, which is the most common malignant primary brain tumor. Major advances in cancer therapeutics such as immune checkpoint inhibitors and chimeric antigen receptor (CAR) T-cell therapy have not yet led to improved outcomes for GBM. Conventional therapy of surgery followed by chemoradiation with or without tumor treating fields remains the standard of care. One of the many approaches to GBM therapy currently being explored is viral therapies. These typically work by selectively lysing target neoplastic cells, called oncolysis, or by the targeted delivery of a therapeutic transgene via a viral vector. In this review, we discuss the underlying mechanisms of action and describe both recent and current human clinical trials using these viruses with an emphasis on promising viral therapeutics that may ultimately break the field’s current stagnant paradigm.

show abstract

Section: Murine Leukemia Virus-based Therapiesmentioning

confidence: 99%

Current Status and Challenges of Oncolytic Virotherapy for the Treatment of Glioblastoma

2023

View full text Add to dashboard Cite

show abstract

“…Of the several presentations of TOCA 511, a retroviral replicating vector encoding yeast cytosine deaminase, administered in combination with extended release 5-flurocytosine, a novel intravenous Phase I trial was notable for obviating the usual administration of TOCA 511 by intratumoral or convection enhanced delivery [15]. Patients scheduled to undergo a planned reresection for recurrent GBM were first given TOCA 511 intravenously and a planned surgical analysis (presence of virus and the transgene cytosine deaminase) was performed as a proof of effective delivery.…”

Section: Salvage Trialsmentioning

confidence: 99%

A selected review of abstracts from the 20th Annual Meeting of the Society for Neuro-Oncology (SNO)

Chamberlain

2016

CNS Oncol.

View full text Add to dashboard Cite

20th Annual Meeting of the Society for neuro-oncology, San Antonio, tX, USA, 18-22 november 2015The Society for Neuro-Oncology is the largest neuro-oncology meeting in the USA that meets annually and provides a multiday venue that showcases new brain cancer clinical trial results and basic research primarily pertaining to gliomas. The Society for Neuro-Oncology 2015 meeting comprising one education day, 2 days of premeetings and 3 days of presentation, over 200 oral presentations and 900 abstracts provides an overview of contemporary neurooncology that includes metastatic disease of the central nervous system as well as primary brain tumors. This review attempts to highlight select abstracts presented at this year's meeting in a short summary that provides a synopsis of a large and multifaceted meeting. A study by the Alliance consortium evaluated in a randomized trial stereotactic radiosurgery (SRS) with or without whole brain radiotherapy (WBRT) in 213 patients with 1-3 brain metastases (BM) (68% lung cancer related) [1]. The primary end point was cognitive progression at 3 months using six cognitive test instruments. Cognitive progression at 3 months (as reflected by immediate recall, delayed recall and verbal fluency) was more frequent following SRS + WBRT compared with SRS only (92 vs 64%). Intracranial tumor control at 3 and 6 months were better in the SRS + WBRT cohort (75.3 and 64.7% with SRS alone vs 93.7 and 88.4% with SRS + WBRT), however, overall survival (OS) was similar in both groups. The authors conclude that in patients with 1-3 BM, SRS only is the preferred therapy with less cognitive impact and similar survival. Not clear, however, from this study was whether the deterioration in cognitive function seen with SRS + WBRT was maintained at 6 months or were there data regarding progressive neurological disease as a cause of death in the two treatment arms. Essentially all studies in BM have failed to show a difference in OS and consequently the significance of this as an end point in BM trials is unclear. Lastly, there were no data regarding the need for salvage therapy in patients treated with SRS only.A study of 51 patients with ALK-rearranged non-small-cell lung cancer and BM all of whom had progressed on crizotinib, an ALK inhibitor, were treated with the recently approved ALK inhibitor alectinib [2]. Patients with ALK + NSCL and BM were a subset of all patients enrolled in one of two prospective Phase II trials of alectinib. The intracranial response was 61% and median For reprint orders, please contact: reprints@futuremedicine.com

show abstract

Ddel-07intravenous Toca 511 Delivery Leads to Viral Dna in Resected HGG

Cited by 2 publications

References 0 publications

Current Status and Challenges of Oncolytic Virotherapy for the Treatment of Glioblastoma

Current Status and Challenges of Oncolytic Virotherapy for the Treatment of Glioblastoma

A selected review of abstracts from the 20th Annual Meeting of the Society for Neuro-Oncology (SNO)

Contact Info

Product

Resources

About